N/A
Manufactured by AbbVie Inc.
19,271 FDA adverse event reports analyzed
Last updated: 2026-04-14
PARICALCITOL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by AbbVie Inc.. The most commonly reported adverse reactions for PARICALCITOL include DEATH, CARDIAC DISORDER, MYOCARDIAL INFARCTION, SEPSIS, CARDIO-RESPIRATORY ARREST. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PARICALCITOL.
Out of 14,024 classified reports for PARICALCITOL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 19,271 FDA FAERS reports that mention PARICALCITOL. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DEATH, CARDIAC DISORDER, MYOCARDIAL INFARCTION, SEPSIS, CARDIO-RESPIRATORY ARREST, DYSPNOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list AbbVie Inc. in connection with PARICALCITOL. Always verify the specific product and NDC with your pharmacist.